Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy

[1]  P. Clayton,et al.  Disorders of bile acid synthesis , 2006, Journal of Inherited Metabolic Disease.

[2]  G. Nandakumar,et al.  Cerebrotendinous xanthomatosis: need for early diagnosis. , 2006, Indian journal of dermatology, venereology and leprology.

[3]  K. Setchell,et al.  Defects in bile acid biosynthesis--diagnosis and treatment. , 2006, Journal of pediatric gastroenterology and nutrition.

[4]  W. Walker.  Pediatric Gastrointestinal Disease , 2004 .

[5]  R. Wevers,et al.  Mutations in the sterol 27-hydoxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis , 2002, Journal of Inherited Metabolic Disease.

[6]  P. Clayton.  Applications of mass spectrometry in the study of inborn errors of metabolism , 2001, Journal of Inherited Metabolic Disease.

[7]  Lee Kw,et al.  Cerebrotendinous xanthomatosis in three siblings from a Chinese family. , 2001 .

[8]  K. F. Ko,et al.  Cerebrotendinous xanthomatosis in three siblings from a Chinese family. , 2001, Singapore medical journal.

[9]  M. A. Croce,et al.  Four novel mutations of sterol 27-hydroxylase gene in Italian patients with cerebrotendinous xanthomatosis. , 1997, Journal of lipid research.

[10]  Y. Tokimura,et al.  Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use , 1994, Journal of the Neurological Sciences.

[11]  G. Tint,et al.  Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis. , 1994, Metabolism: clinical and experimental.

[12]  D. Russell,et al.  Bile acid biosynthesis. , 1992, Biochemistry.

[13]  Y. Matsuzawa,et al.  Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. , 1991, Metabolism: clinical and experimental.

[14]  Y. Seyama,et al.  Cerebrotendinous xanthomatosis: Clinical and biochemical evaluation of eight patients and review of the literature , 1991, Journal of the Neurological Sciences.

[15]  H. Jörnvall,et al.  Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. , 1989, The Journal of biological chemistry.

[16]  J. C. van der Molen,et al.  Bile acid therapies applied to patients suffering from cerebrotendinous xanthomatosis. , 1985, Clinica chimica acta; international journal of clinical chemistry.

[17]  J. Sjövall,et al.  Fast atom bombardment mass spectrometry in the diagnosis of cerebrotendinous xanthomatosis. , 1985, Scandinavian journal of clinical and laboratory investigation.

[18]  H. Yasuhara,et al.  Membrane effects of various drugs on isolated rat hepatocytes and erythrocytes. , 1985, Toxicology and applied pharmacology.

[19]  S. Shefer,et al.  Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. , 1984, The New England journal of medicine.

[20]  G. Tint,et al.  A 25-hydroxylation pathway of cholic acid biosynthesis in man and rat. , 1976, The Journal of clinical investigation.

[21]  G. Salen,et al.  Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis. , 1975, Biochemical medicine.

[22]  G. Salen.  Cholestanol deposition in cerebrotendinous xanthomatosis. A possible mechanism. , 1971, Annals of internal medicine.

[23]  P. Swanson,et al.  Cerebrotendinous Xanthomatosis: The Storage of Cholestanol Within the Nervous System , 1968 .